These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30430229)

  • 1. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Moorcraft SY; Khan K; Peckitt C; Watkins D; Rao S; Cunningham D; Chau I
    Clin Colorectal Cancer; 2014 Dec; 13(4):232-8. PubMed ID: 25442814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
    Roehrle J; Kasper S; Treckmann JW; Markus P; Schumacher B; Albers D; Wendling J; Ting S; Mende B; Maßmann M; Markus M; Virchow I; Rosery V; Laue K; Zaun G; Kostbade K; Pogorzelski M; Reissig TM; Liffers ST; Schmid K; Schildhaus HU; Schuler M; Siveke JT; Wiesweg M
    Oncol Res Treat; 2023; 46(4):140-150. PubMed ID: 36720216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
    Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
    Hann A; Bohle W; Egger J; Zoller WG
    Z Gastroenterol; 2016 Oct; 54(10):1138-1142. PubMed ID: 27723905
    [No Abstract]   [Full Text] [Related]  

  • 8. Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.
    Hegewisch-Becker S; Aldaoud A; Wolf T; Krammer-Steiner B; Linde H; Scheiner-Sparna R; Hamm D; Jänicke M; Marschner N;
    Int J Cancer; 2019 Mar; 144(5):981-990. PubMed ID: 30006989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
    Zahir MN; Jabbar AA
    Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery?
    Frigerio I; Regi P; Giardino A; Scopelliti F; Girelli R; Bassi C; Gobbo S; Martini PT; Capelli P; D'Onofrio M; Malleo G; Maggino L; Viviani E; Butturini G
    Ann Surg Oncol; 2017 Aug; 24(8):2397-2403. PubMed ID: 28516291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
    Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
    Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
    Bednar F; Zenati MS; Steve J; Winters S; Ocuin LM; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2017 May; 24(5):1406-1413. PubMed ID: 27896518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer.
    Tsang ES; Wong HL; Wang Y; Renouf DJ; Cheung WY; Lim HJ; Gill S; Loree JM; Kennecke HF
    Am J Clin Oncol; 2019 Feb; 42(2):196-201. PubMed ID: 30499841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
    Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO
    Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.